Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Diffuse Parenchymal Lung Disease
When do you consider systemic therapy for patients with progressive fibrosing mediastinitis?
Related Questions
How do you approach the use of benzodiazepines in patients with chronic medical illnesses that may be susceptible to respiratory compromise (e.g., CHF, COPD, ILD)?
What is the duration of steroids that you prescribe for organizing pneumonia?
How would you approach management of a patient with seropositive RA and UIP-ILD, with concern for active lung disease?
What criteria do you use to determine when to start a steroid-sparing agent for hypersensitivity pneumonitis?
Do you seek pathologic confirmation before proceeding with empiric immunosuppressive therapy in symptomatic patients with radiographic NSIP?
Would you consider adding or switching to pirfenidone for a patient with progressing UIP (based on imaging and PFTs) who is currently on nintedanib?
Do you monitor CBCs to assess for drug toxicity in patients on nintedanib?
How do you approach pre-operative risk assessment and optimization in a patient with interstitial lung disease?
What criteria do you use to decide when to perform a BAL in hypersensitivity pneumonitis?
Do you routinely integrate telomere length testing into the evaluation of patients with ILD?
